A cohort study finds upadacitinib improves lung survival rates similar to tofacitinib in MDA5-positive patients, suggesting comparable safety.
UPA was found to be non-inferior to TOFA in improving 6-month lung transplantation-free survival among patients with MDA5⁺DM-ILD, with comparable safety.
No takes yet. Share an insight, caveat, or question.
Xia et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: